Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma: time for a precision medicine approach.

Hematology. American Society of Hematology. Education Program - 1 Jan 2015

Friedberg Jonathan W

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non Hodgkin lymphoma in the Western world, and is potentially curable with standard R-CHOP chemoimmunotherapy. Historically, clinical risk assessments provided prognostic information, but did not define treatment approach. We are now in an era where the heterogeneity of DLBCL is defined genetically and molecularly, and rational subset-specific...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophosphamide
Share to Doxorubicin
Share to Lymphoma, Large B-Cell, Diffuse

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Medical Oncology

Share to Prednisolone

Share to Proto-Oncogene Proteins c-bcl-2

Share to Proto-Oncogene Proteins c-myc

Share to Vincristine

Source

Identifiers

PMID: 26637779
DOI: 10.1182/asheducation-2015.1.618

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma: time for a precision medicine approach.PMID 26637779Read ↗

Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular PhenotypeSemantic proximity Read ↗

Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?Semantic proximity Read ↗

Classifying DLBCL Subtypes for Optimal Treatment.Semantic proximity Read ↗

Primary mediastinal large B-cell lymphomaSemantic proximity Read ↗

Double-hit lymphomas: current paradigms and novel treatment approaches.Semantic proximity Read ↗

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphomaSemantic proximity Read ↗

Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.Semantic proximity Read ↗

Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin LymphomaSemantic proximity Read ↗

Double hit lymphoma: from biology to therapeutic implications.Semantic proximity Read ↗

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapySemantic proximity Read ↗

[Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].Semantic proximity Read ↗

Molecular classification and therapeutics in diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.